FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Update

FibroBiologics Inc. (NASDAQ:FBLG) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 851,743 shares, a growth of 128.4% from the January 15th total of 372,855 shares. Approximately 1.5% of the company’s shares are short sold. Based on an average trading volume of 689,374 shares, the short-interest ratio is presently 1.2 days. Based on an average trading volume of 689,374 shares, the short-interest ratio is presently 1.2 days. Approximately 1.5% of the company’s shares are short sold.

FibroBiologics Stock Performance

FBLG stock traded down $0.01 on Thursday, hitting $0.25. 334,363 shares of the company’s stock were exchanged, compared to its average volume of 1,520,537. The firm has a 50 day moving average price of $0.29 and a two-hundred day moving average price of $0.42. FibroBiologics has a 12-month low of $0.22 and a 12-month high of $1.70. The stock has a market cap of $16.36 million, a P/E ratio of -0.51 and a beta of -0.60.

Wall Street Analysts Forecast Growth

FBLG has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of FibroBiologics in a research report on Friday, January 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research note on Thursday, January 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of FibroBiologics in a research report on Tuesday, January 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, FibroBiologics currently has an average rating of “Hold” and an average target price of $10.00.

Insider Activity at FibroBiologics

In related news, General Counsel Ruben A. Garcia purchased 140,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was purchased at an average price of $0.34 per share, with a total value of $47,600.00. Following the completion of the purchase, the general counsel owned 140,000 shares of the company’s stock, valued at approximately $47,600. The trade was a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 13.00% of the company’s stock.

Hedge Funds Weigh In On FibroBiologics

Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in FibroBiologics in the 1st quarter worth approximately $29,000. XTX Topco Ltd raised its holdings in shares of FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after buying an additional 28,276 shares during the last quarter. Ethos Financial Group LLC lifted its stake in shares of FibroBiologics by 100.0% during the second quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock worth $30,000 after buying an additional 24,424 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of FibroBiologics during the second quarter valued at $37,000. Finally, Marshall Wace LLP purchased a new stake in shares of FibroBiologics during the second quarter valued at $49,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.